e-learning
resources
ERJ
2008
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition
Dony E., Lai Y-J., Dumitrascu R., Pullamsetti S. S., Savai R., Ghofrani H. A., Weissmann N., Schudt C., Flockerzi D., Seeger W., Grimminger F., Schermuly R. T.
Source:
Eur Respir J 2008; 31: 599-610
Journal Issue:
March
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Dony E., Lai Y-J., Dumitrascu R., Pullamsetti S. S., Savai R., Ghofrani H. A., Weissmann N., Schudt C., Flockerzi D., Seeger W., Grimminger F., Schermuly R. T.. Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition. Eur Respir J 2008; 31: 599-610
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats
Source: Eur Respir J 2011; 37: 1104-1118
Year: 2011
Involvement of FHL1 in vascular remodelling
Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling
Year: 2006
Apoptosis and cell proliferation in chronic hypoxic pulmonary hypertension
Source: Lung Science Conference 2007 - Translational research in pulmonary disease: Hypoxia-driven mechanisms
Year: 2007
In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy
Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension
Year: 2007
PDGF promotes pulmonary artery smooth muscle cell proliferation and migration in pulmonary arterial hypertension
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Shroom expression is attenuated in pulmonary arterial hypertension
Source: Eur Respir J 2008; 32: 871-880
Year: 2008
Pulmonary hypertension: the science behind the disease spectrum
Source: Eur Respir Rev 2012; 21: 19-26
Year: 2012
Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation
Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling
Year: 2006
Role of anti-proliferative therapy in PAH
Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension
Year: 2008
Mast cells promote lung vascular remodelling in pulmonary hypertension
Source: Eur Respir J 2011; 37: 1400-1410
Year: 2011
Pathobiology of pulmonary arterial hypertension
Source: Eur Respir J 2002; 20: 1559-1572
Year: 2002
Tyrosine kinase inhibition in pulmonary hypertension: the anti-proliferative approach
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Impairment of respiratory muscle function in pulmonary hypertension
Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension
Year: 2007
Contribution of angiopoietin/Tie2 pathway to pulmonary artery smooth muscle hyperplasia in idiopathic pulmonary hypertension
Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Year: 2005
Serotonin transporter genes, pulmonary haemodynamics and pulmonary hypertension
Source: Annual Congress 2005 - Scientific year in review
Year: 2005
IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Pulmonary hypertension in chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 892-905
Year: 2003
The role of growth and differentiation factor 15 (GDF-15) in the development of skeletal muscle wasting in pulmonary arterial hypertension (PAH)
Source: International Congress 2015 – New insights into exercise and muscle performance
Year: 2015
Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target
Source: Eur Respir J 2011; 38: 1453-1460
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept